Clinical Validation of the Management Process for Renal Anemia in Maintenance Hemodialysis Patients

Launched by HONG DAQING · Jun 12, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new way to manage anemia in patients who are undergoing regular hemodialysis, a treatment for kidney failure. Anemia is a condition where you don't have enough healthy red blood cells, which can make you feel weak and tired. The goal of the trial is to see if a specific management process can help improve the hemoglobin levels (the part of your blood that carries oxygen) in these patients better than the usual care they receive from their primary doctors. By doing this, the researchers hope to set up a better system for managing anemia in these patients, especially at local healthcare centers.

To be eligible for this trial, participants must be at least 18 years old and have been receiving hemodialysis at least twice a week for the past three months. It's important that they plan to continue hemodialysis for at least six months and willingly choose to join the study. However, people who are planning to get a kidney transplant or have certain blood disorders or infections cannot participate. If you join the trial, you can expect to receive care and guidance specifically focused on managing your anemia, which may help improve your overall health and quality of life.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • ① Age over 18 years old; ② Receive regular hemodialysis at least twice a week for at least 3 months, and have no plans to stop hemodialysis within 6 months since the start of the trial; ③ The patient voluntarily participated in this study.
• Exclusion Criteria:
• • Patients who have planned to undergo kidney transplantation or terminate hemodialysis during the study period; ② Previous history of bone marrow hematopoietic system diseases, such as combined myelodysplastic syndrome, multiple myeloma, and other diseases; ③ Any known hereditary blood disease, such as thalassemia, sickle cell anemia, pure red blood cell aplasia, etc.; ④ Active or chronic gastrointestinal bleeding; ⑤ There was a severe infection within one week prior to screening.